A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.

被引：0
|
作者：
Papadopoulos, Kyriakos P.
Sahebjam, Solmaz
Kelley, Robin Katie
Tolcher, Anthony W.
Razak, Albiruni R. A.
Patnaik, Amita
Bedard, Philippe L.
Arcos, Rebecca
Adriaens, Lieve
Brownstein, Carrie M.
Lowy, Israel
Gao, Bo
DiCioccio, A. Thomas
Trail, Pamela
Siu, Lillian L.
机构：
[1] START Ctr Canc Care, San Antonio, TX USA
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[5] Univ Toronto, Dept Med, Div Med Oncol & Hematol, Princess Margaret Canc Ctr,Univ Hlth Network, Toronto, ON, Canada
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies.
    Papadopoulos, K. P.
    Chau, N. G.
    Patnaik, A.
    Adriaens, L.
    Lalani, A. S.
    Daly, C.
    Siu, L. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] A phase Ib study of combined angiogenesis blockade with REGN910 (SAR307746), a selective monoclonal antibody (MAb) against angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid tumor malignancies.
    Adriaens, Lieve
    Papadopoulos, Kyriakos P.
    Graham, Donna M.
    Patnalk, Amita
    Razak, Albiruni R. A.
    Tolcher, Anthony W.
    Siu, Lillian L.
    Rasco, Drew Warren
    Trail, Pamela
    Brownstein, Carrie M.
    Lowy, Israel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Kelley, Robin Kate
    Tolcher, Anthony W.
    Razak, Albiruni R. Abdul
    Van Loon, Katherine
    Patnaik, Amita
    Bedard, Philippe L.
    Alfaro, Ariceli A.
    Beeram, Muralidhar
    Adriaens, Lieve
    Brownstein, Carrie M.
    Lowy, Israel
    Kostic, Ana
    Trail, Pamela A.
    Gao, Bo
    DiCioccio, A. Thomas
    Siu, Lillian L.
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1348 - 1355
  • [4] Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hcpatocellular carcinoma (HCC) Cohort.
    Kelley, Robin Kate
    Siu, Lillian L.
    Van Loon, Katherine
    Tolcher, Anthony W.
    Razak, Albiruni R. A.
    Zlyeh, Sharvina
    Beeram, Muralidhar
    Bedard, Philippe L.
    Arcos, Rebecca
    Gao, Bo
    Trail, Pamela
    Adriaens, Lieve
    Brownstein, Carrie M.
    Lowy, Israel
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies
    Papadopoulos, Kyriakos P.
    Graham, Donna M.
    Tolcher, Anthony W.
    Razak, Albiruni R. A.
    Patnaik, Amita
    Bedard, Philippe L.
    Rasco, Drew Warren
    Amaya, Alex
    Moore, Kathleen N.
    Konner, Jason A.
    Matei, Daniela
    Martin, Lainie P.
    Adriaens, Lieve
    Brownstein, Carrie M.
    Lowy, Israel
    Gao, Bo
    Kostic, Ana
    DiCioccio, A. Thomas
    Trail, Pamela
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.
    Papadopoulos, Kyriakos P.
    Lakhani, Nehal J.
    Johnson, Melissa Lynne
    Park, Haeseong
    Wang, Ding
    Yap, Timothy A.
    Dowlati, Afshin
    Maki, Robert G.
    Lynce, Filipa
    Ulahannan, Susanna Varkey
    Kelly, Karen
    Sims, Tasha Nicholle
    Bredlau, Amy-Lee
    Bramble, Derrick
    Ortiz, Ana Gonzalez
    Zhu, Min
    Chen, Huanyu
    Karasarides, Maria
    Kroog, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] REGN910, a fully-human, Ang2-specific monoclonal antibody, inhibits tumor growth as a monotherapy and dramatically potentiates the effects of VEGF Trap (aflibercept)
    Daly, Christopher
    Castanaro, Carla
    Adler, Alexander P.
    Eichten, Alexandra
    Lalani, Alshad S.
    Papadopoulos, Nicholas J.
    Thurston, Gavin
    CANCER RESEARCH, 2011, 71
  • [8] Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies.
    Attard, G
    Plummer, RE
    De Bono, JS
    Bale, C
    Fong, P
    Barrett, M
    Fox, NL
    Howard, T
    Ullrich, S
    Calvert, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9060S - 9060S
  • [9] Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies.
    Pacey, S
    Plummer, RE
    Attard, G
    Bale, C
    Calvert, AH
    Blagden, S
    Fox, NL
    Corey, A
    de Bono, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 205S - 205S
  • [10] A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
    Chiorean, Elena Gabriela
    LoRusso, Patricia
    Strother, Robert Matthew
    Diamond, Jennifer R.
    Younger, Anne
    Messersmith, Wells A.
    Adriaens, Lieve
    Liu, Liming
    Kao, Richard J.
    DiCioccio, Albert Thomas
    Kostic, Ana
    Leek, Russell
    Harris, Adrian
    Jimeno, Antonio
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2695 - 2703
12345